SAN DIEGO--(BUSINESS WIRE)--Feb. 26, 2019--
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic
testing solutions, cellular-based virology assays and molecular
diagnostic systems, announced today that it will present at the
following upcoming conferences:
-
Raymond James & Associates 40th Annual Institutional
Investors Conference to be held at the J.W. Marriott Grande Lakes
hotel in Orlando, Florida on Wednesday, March 6, 2019 at 12:10 p.m.
Eastern Time (9:10 a.m. Pacific Time).
-
Barclays Global Healthcare Conference, to be held at the Loews Miami
Beach hotel in Miami Beach, Florida on Thursday, March 14, 2019 at
9:00 a.m. Eastern Time (6:00 a.m. Pacific Time).
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present on the specified days
with question-and-answer sessions scheduled immediately following each
presentation. During the presentations, the company will discuss
business and financial developments and trends. The company's statements
may contain or constitute material information that has not been
previously disclosed.
A live webcast and audio archive of each presentation will be available
via the Investor Relations section of the company’s website at http://ir.quidel.com
or by clicking the links below.
Raymond James: http://wsw.com/webcast/rj113/qdel/
Barclays: https://event.webcasts.com/starthere.jsp?ei=1233478&tp_key=c88f08b305&tp_special=8
Participants should allow approximately five to ten minutes prior to the
presentation's start time to visit the site and download any streaming
media software needed to listen to the Internet webcast. A replay of the
webcast will also be available on the company’s website for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being of people
around the globe through the development of diagnostic solutions that
can lead to improved patient outcomes and provide economic benefits to
the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct
Detection, Thyretain®, Triage® and InflammaDry® leading brand names, as
well as under the new Solana®, AmpliVue® and Lyra®
molecular diagnostic brands, Quidel’s products aid in the detection and
diagnosis of many critical diseases and conditions, including, among
others, influenza, respiratory
syncytial virus, Strep A, herpes, pregnancy, thyroid
disease and fecal
occult blood. Quidel's recently acquired Triage® system of tests
comprises a comprehensive test menu that provides rapid, cost-effective
treatment decisions at the point-of-care (POC), offering a diverse
immunoassay menu in a variety of tests to provide diagnostic answers for
quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I and qualitative
TOX Drug Screen. Quidel’s research and development engine is also
developing a continuum of diagnostic solutions from advanced immunoassay
to molecular diagnostic tests to further improve the quality of
healthcare in physicians’ offices and hospital and reference
laboratories. For more information about Quidel’s comprehensive product
portfolio, visit quidel.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190226006104/en/
Source: Quidel Corporation
Quidel Contact:
Quidel Corporation
Randy Steward
Chief
Financial Officer
(858) 552-7931
Media and Investors Contact:
Quidel Corporation
Ruben Argueta
(858)
646-8023
rargueta@quidel.com